

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:13:53 ON 25 MAY 2006

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:14:07 ON 25 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2006 HIGHEST RN 885512-85-6

DICTIONARY FILE UPDATES: 24 MAY 2006 HIGHEST RN 885512-85-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s clitocone/cn

L1 0 CLITOCONE/CN

=> s clitocine/cn

L2 1 CLITOCINE/CN


=> d L2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 105798-74-1 REGISTRY
ED Entered STN: 21 Dec 1986
CN β -D-Ribofuranosylamine, N-(6-amino-5-nitro-4-pyrimidinyl)- (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN Clitocine
FS STEREOSEARCH
MF C9 H13 N5 O6
CI COM
SR CA
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, DDFU,
DRUGU, IPA, MEDLINE, NAPRALERT, PROUSDDR, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

18 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
18 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> sel L2

E1 THROUGH E2 ASSIGNED

=> index bioscience patents

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ENCOMPAT2' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
12.19	12.40

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 10:15:00 ON 25 MAY 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s E1-E2

1	FILE ADISCTI
1	FILE AGRICOLA
16	FILE BIOSIS
2	FILE BIOTECHABS
2	FILE BIOTECHDS
4	FILE BIOTECHNO
1	FILE CABA

25 FILE CAPLUS
 4 FILE CROPU
 9 FILE DDFU
 1 FILE DISSABS
 9 FILE DRUGU
 13 FILE EMBASE
 3 FILE ESBIODBASE
 2 FILE IFIPAT
 37 FILES SEARCHED...
 1 FILE JICST-EPLUS
 4 FILE MEDLINE
 8 FILE PASCAL
 1 FILE PHIN
 4 FILE PROUSDDR
 27 FILE SCISEARCH
 9 FILE TOXCENTER
 5 FILE USPATFULL
 1 FILE WPIDS
 1 FILE WPINDEX
 8 FILE CASREACT
 2 FILE EPFULL
 77 FILES SEARCHED...
 13 FILE PCTFULL

28 FILES HAVE ONE OR MORE ANSWERS, 92 FILES SEARCHED IN STNINDEX

L3 QUE (CLITOCINE/BI OR 105798-74-1/BI)

=> file biosis caplus embase pascal scisearch uspatfull pctfull		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.83	14.23

FILE 'BIOSIS' ENTERED AT 10:17:02 ON 25 MAY 2006
 Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 10:17:02 ON 25 MAY 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:17:02 ON 25 MAY 2006
 Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'PASCAL' ENTERED AT 10:17:02 ON 25 MAY 2006
 Any reproduction or dissemination in part or in full,
 by means of any process and on any support whatsoever
 is prohibited without the prior written agreement of INIST-CNRS.
 COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 10:17:02 ON 25 MAY 2006
 Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 10:17:02 ON 25 MAY 2006
 CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 10:17:02 ON 25 MAY 2006
 COPYRIGHT (C) 2006 Univentio

=> s E1-E2
 L4 107 (CLITOCINE/BI OR 105798-74-1/BI)

=> dup rem L4
 PROCESSING COMPLETED FOR L4
 L5 60 DUP REM L4 (47 DUPLICATES REMOVED)

=> s L5 and (cancer or tumor or p53 or neoplas? or chemother?)
L6 21 L5 AND (CANCER OR TUMOR OR P53 OR NEOPLAS? OR CHEMOTHER?)

=> s L5 and (nonsense or transcription)
L7 11 L5 AND (NONSENSE OR TRANSCRIPTION)

=> s L6 not py>2002
L8 8 L6 NOT PY>2002

=> s L7 not py>2002
L9 4 L7 NOT PY>2002

=> d L8 1-8 ti abs bib

L8 ANSWER 1 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI SYNTHESIS AND BIOLOGICAL ACTIVITY OF CARBOCYCLIC **CLITOCINE**.
AN 1991:445330 BIOSIS
DN PREV199141083065; BR41:83065
TI SYNTHESIS AND BIOLOGICAL ACTIVITY OF CARBOCYCLIC **CLITOCINE**.
AU BAXTER A D [Reprint author]; PENN C R; STORER R; WEIR N G; WOODS J M
CS DEP MEDICINAL CHEMISTRY, GLAXO GROUP RESEARCH LTD, GREENFORD, MIDDLESEX
UB6 OHE, UK
SO Nucleosides and Nucleotides, (1991) Vol. 10, No. 1-3, pp. 393-396.
Meeting Info.: PROCEEDINGS OF THE 9TH INTERNATIONAL ROUND TABLE DISCUSSION
ON NUCLEOSIDES, NUCLEOTIDES, AND THEIR BIOLOGICAL APPLICATIONS, UPPSALA,
SWEDEN, JULY 30-AUGUST 3, 1990. NUCLEOSIDES NUCLEOTIDES.
CODEN: NUNUD5. ISSN: 0732-8311.
DT Conference; (Meeting)
FS BR
LA ENGLISH
ED Entered STN: 8 Oct 1991
Last Updated on STN: 8 Oct 1991

L8 ANSWER 2 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI SYNTHESIS INTRAMOLECULAR HYDROGEN BONDING AND BIOCHEMICAL STUDIES OF
CLITOCINE A NATURALLY OCCURRING EXOCYCLIC AMINO NUCLEOSIDE.
AB The total synthesis of **clitocine** [6-amino-5-nitro-4-(β -D-
ribofuranosylamino)pyrimidine] (1), a nucleoside recently isolated from
the mushroom *Clitocybe inversa*, has been accomplished. Glycosylation of
4,6-diamino-5-nitropyrimidine (4) with 1-O-acetyl-2, 3,
5-tri-O-benzoyl-D-ribofuranose afforded the protected nucleoside
6-amono-5-nitro-4-[(2, 3, 5-tri-O-benzoyl- β -D-
ribofuranosyl)aminopyrimidine (5) in good yield exclusively as the
 β -anomer. Deprotection of 5 with NaOMe/MeOH gave 1 as an 11.5:1
mixture of the β - and α -anomers, respectively.
Recrystallization from MeOH, followed by chromatography, afforded 1
containing less than 1% of its α -anomer. X-ray crystal data
revealed a planar aglycon moiety in **clitocine** with each oxygen
atom of the nitro group intramolecularly hydrogen bonded to the hydrogen
atoms of the two adjacent amino functions. **Clitocine** inhibited
L1210 cells in vitro with an ID50 of 3×10^{-8} M. **Clitocine**
was also found to be a substrate and inhibitor of adenosine kinase with a
Ki value of 3×10^{-6} M.
AN 1988:267129 BIOSIS
DN PREV198886006373; BA86:6373
TI SYNTHESIS INTRAMOLECULAR HYDROGEN BONDING AND BIOCHEMICAL STUDIES OF
CLITOCINE A NATURALLY OCCURRING EXOCYCLIC AMINO NUCLEOSIDE.
AU MOSS R J [Reprint author]; PETRIE C R; MEYER R B JR; NORD L D; WILLIS R C;
SMITH R A; LARSON S B; KINI G D; ROBINS R K
CS NUCLEIC ACID RES INST, 3300 HYLAND AVENUE, MESA, CALIF 92626, USA
SO Journal of Medicinal Chemistry, (1988) Vol. 31, No. 4, pp. 786-790.
CODEN: JMCMAR. ISSN: 0022-2623.
DT Article
FS BA

LA ENGLISH
 ED Entered STN: 2 Jun 1988
 Last Updated on STN: 2 Jun 1988

L8 ANSWER 3 OF 8 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Cytotoxic activity of Tricholomatales determined with murine and human cancer cell lines
 AB The cytotoxic activity of 22 methanol extracts of fresh fruiting bodies of the Tricholomatales order was evaluated with two murine cancer cell lines (L1210 and 3LL). The 8 extracts that inhibited the growth of at least one murine cancer cell line were then evaluated with 4 human cancer cell lines (K-562, U251, DU145, MCF7). Four of them had significant cytotoxic activity (IC50 less than or equal to 20 mug/ml) against at least one human cancer cell line. *Lepista inversa*, with an IC50 less than or equal to 20 mug/ml against the 4 human cancer cell lines tested and an activity either equal to or greater than that of a bark extract from *Taxus baccata* L., used as positive control, appeared to be the most promising species.
 AN 2002:538721 SCISEARCH
 GA The Genuine Article (R) Number: 563XP
 TI Cytotoxic activity of Tricholomatales determined with murine and human cancer cell lines
 AU Bezivin C (Reprint); Lohezic F; Sauleau P; Amoros M; Boustie J
 CS Lab Pharmacognosie & Mycol, UPRES EA Synth & Extract Mol Visee Therapeut 2234, Ave Pr Leon Bernard, F-35043 Rennes, France (Reprint); Lab Pharmacognosie & Mycol, UPRES EA Synth & Extract Mol Visee Therapeut 2234, F-35043 Rennes, France
 CYA France
 SO PHARMACEUTICAL BIOLOGY, (2002) Vol. 40, No. 3, pp. 196-199. ISSN: 1388-0209.
 PB SWETS ZEITLINGER PUBLISHERS, P O BOX 825, 2160 SZ LISSE, NETHERLANDS.
 DT Article; Journal
 LA English
 REC Reference Count: 12
 ED Entered STN: 12 Jul 2002
 Last Updated on STN: 12 Jul 2002
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L8 ANSWER 4 OF 8 USPATFULL on STN
 TI Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
 AB A method of inhibiting growth, transformation and/or metastasis of mammalian cells, particularly epithelial cells, in which activity of at least one enzyme, which participates in purine metabolism or regulation of nucleotide levels or the relative ratios of their phosphorylated states, is elevated. In particular, a method of inhibiting transformation, growth and/or metastasis of mammalian cells in which a DNA tumor virus, a DNA tumor virus factor or other factor which has an equivalent effect on cells has acted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AN 94:55549 USPATFULL
 TI Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
 IN Kaddurah-Daouk, Rima, Watertown, MA, United States
 Lillie, James W., Somerville, MA, United States
 Burbaum, Jonathan J., Cambridge, MA, United States
 PA Amira, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 5324731 19940628
 AI US 1990-610418 19901107 (7)
 RLI Continuation-in-part of Ser. No. US 1990-467147, filed on 18 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-344963, filed on 28 Apr 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-310773, filed on 14 Feb 1989,

now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Lahive & Cockfield
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 40 Drawing Figure(s); 39 Drawing Page(s)
LN.CNT 2730

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 8 USPATFULL on STN
TI Substituted pyrimido[5,4-d]pyrimidine nucleosides
AB α and β -ribonucleosides of substituted pyrimido[5,4-d]pyrimidines are used in treating malignant tumors in vivo. A novel synthesis for preparing these compounds and other related compounds is further disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 91:66895 USPATFULL
TI Substituted pyrimido[5,4-d]pyrimidine nucleosides
IN Robins, Roland K., Irvine, CA, United States
Revankar, Ganapathi R., Irvine, CA, United States
Sanghvi, Yogesh S., Irvine, CA, United States
PA Nucleic Acid Research Institute, Costa Mesa, CA, United States (U.S. corporation)
PI US 5041542 19910820
AI US 1988-202787 19880603 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Brown, Johnnie R.; Assistant Examiner: Crane, L. Eric
LREP Boswell, Herb
CLMN Number of Claims: 3
ECL Exemplary Claim: 2,3
DRWN No Drawings
LN.CNT 1060

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN ADENOSINE ANALOGUES AND METHOD OF INCREASING ADENOSINE RELEASE
TIFR ANALOGUES DE L'ADENOSINE ET PROCEDE D'INTENSIFICATION DE LA LIBERATION DE L'ADENOSINE
ABEN Nucleoside analogues such as ribofuranosyl-beta-D-pyrrolopyrimidine compounds and ribofuranosyl pyrrolopyrimidine N-oxide compounds and pharmaceutically acceptable salts and mixtures thereof. Compositions comprising these compounds and pharmaceutically acceptable carriers have also been disclosed. The invention further includes ribofuranosyl compounds having the anomeric position substituted with substituents selected from the group consisting of:
-O-(C1-C18)alkyl,
-O-(C1-C18)acyl, halogen, O-tosyl, or -OSO₂R₁₁, wherein R₁₁ is - (C1-C18)alkyl or - (C6-C24)aryl.
Methods of preparing said compounds have also been disclosed. Methods of treating a disease or condition such as inflammation, certain heart conditions, gastric ulcers, osteoarthritis, neutrophil function, or promoting vasodilation, among others comprise administering to a subject in need of the treatment an adenosine kinase activity inhibitory effective amount of claimed compounds or compositions thereof.
ABFR L'invention se rapporte a des analogues de nucleosides tels que des composes de

ribofuranosyl-beta-D-pyrrolopyrimidine et des composes de ribofuranosyl pyrrolopyrimidine N-oxyde et des sels pharmaceutiquement acceptables et des melanges de ceux-ci. L'invention se rapporte egalement a des compositions comprenant ces composes et ces excipients pharmaceutiquement acceptables. L'invention comprend en outre des composes de ribofuranosyl ayant la position anomerique substituee par des substituants selectionnes parmi le groupe constitue par -O-(C1-C18)alkyle, -O-(C1-C18)acyle, halogene, O-tosyle, ou -OSO₂R₁₁ dans lequel R₁₁ represente -(C1-C18)alkyle ou -(C6-C24)aryle. Des procede de preparation de ces composes sont egalement decrits. Des procedes pour traiter d'une maladie ou un etat pathologique, tel qu'une inflammation, certaines maladies du coeur, des ulceres gastriques, l'arthrose, la fonction neutrophile ou pour faciliter la vasodilatation, notamment, consistent a administrer a un sujet necessitant ce traitement une quantite efficace inhibitrice de l'activite de l'adenosine kinase des composes revendiques ou des compositions de ceux-ci.

AN 1994006438 PCTFULL ED 20020513
 TIEN ADENOSINE ANALOGUES AND METHOD OF INCREASING ADENOSINE RELEASE
 TIFR ANALOGUES DE L'ADENOSINE ET PROCEDE D'INTENSIFICATION DE LA LIBERATION DE L'ADENOSINE
 IN CARSON, Dennis, A.;
 COTTAM, Howard, B.
 PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
 LA English
 DT Patent
 PI WO 9406438 A1 19940331
 DS W: AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ
 LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA VN AT BE
 CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
 CM GA GN ML MR NE SN TD TG
 AI WO 1993-US8284 A 19930831
 PRAI US 1992-7/944,134 19920911
 L8 ANSWER 7 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED
 TIFR PROCEDE D'INHIBITION DE LA TRANSFORMATION, DE LA CROISSANCE ET DE LA METASTASE DE CELLULES DANS LESQUELLES L'ACTIVITE ENZYMATIQUE METABOLIQUE PURIQUE EST ELEVEE
 ABEN A method of inhibiting growth, transformation, and/or metastasis of mammalian cells, particularly epithelial cells, in which activity of at least one enzyme, which participates in purine metabolism or regulation of nucleotide levels or the relative ratios of their phosphorylated states, is elevated. In particular, a method of inhibiting transformation, growth and/or metastasis of mammalian cells in which a DNA tumor virus, a DNA tumor virus factor or other factor which has an equivalent effect on cells has acted.
 ABFR Procede d'inhibition de la croissance, de la transformation et/ou de la metastase de cellules mammiferes, notamment de cellules epitheliales, dans lesquelles l'activite d'au moins une enzyme, laquelle participe au metabolisme ou a la regulation purique de niveaux de nucleotides ou aux rapports relatifs de leurs etats phosphoryles, est elevee. L'invention concerne notamment un procede

d'inhibition de la transformation, de la croissance et/ou de la
metastase de cellules mammiferes
dans lesquelles un virus oncogene d'ADN, un facteur de virus oncogene
d'ADN ou un autre facteur
ayant un effect equivalent sur les cellules a agi.

AN 1992008456 PCTFULL ED 20020513
TIEN METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN
WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED
TIFR PROCEDE D'INHIBITION DE LA TRANSFORMATION, DE LA CROISSANCE ET DE LA
METASTASE DE CELLULES DANS LESQUELLES L'ACTIVITE ENZYMATIQUE METABOLIQUE
PURIQUE EST ELEVEE
IN KADDURAH-DAOUK, Rima;
LILLIE, James, W.
PA AMIRA, INC.
LA English
DT Patent
PI WO 9208456 A2 19920529
DS W: AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE
AI WO 1991-US8275 A 19911107
PRAI US 1990-610,418 19901107

L8 ANSWER 8 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC
ENZYME ACTIVITY
TIFR INHIBITION DE LA TRANSFORMATION DE CELLULES AYANT UNE ACTIVITE D'ENZYME
METABOLIQUE DE PURINE ELEVEE
ABEN A method of inhibiting growth rate, transformation or metastasis of
mammalian cells,
particularly epithelial cells, in which activity of at least one enzyme
which participates in purine
metabolism and regulation of nucleotide levels is elevated. In
particular, a method of inhibiting
transformation of mammalian cells by a DNA tumor virus, a DNA
tumor virus factor or other factor
which has an equivalent effect on cells.
ABFR Procede permettant d'inhiber le taux de croissance, la transformation ou
metastase de cellules
de mammiferes, notamment de cellules epitheliales, ou l'activite d'un
enzyme au moins, participant
dans les taux de metabolisme de la purine et de regulation des
nucleotides, est elevee. On decrit en
particulier un procede permettant d'inhiber la transformation de
cellules de mammifere par un virus
oncogene de l'ADN, un facteur de virus oncogene de l'ADN, ou par
d'autres facteurs ayant un effet
semblable sur les cellules.

AN 1990009192 PCTFULL ED 20020513
TIEN INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC
ENZYME ACTIVITY
TIFR INHIBITION DE LA TRANSFORMATION DE CELLULES AYANT UNE ACTIVITE D'ENZYME
METABOLIQUE DE PURINE ELEVEE
IN KADDURAH-DAOUK, Rima;
DAOUK, Ghaleb;
SCHIMMEL, Paul, R.;
KINGSTON, Robert;
LILLIE, James, W.;
GREEN, Michael;
PUTNEY, Scott, D.
PA MASSACHUSETTS INSTITUTE OF TECHNOLOGY;
HARVARD UNIVERSITY
LA English
DT Patent
PI WO 9009192 A1 19900823
DS W: AT AU BE CA CH DE DK ES FR GB IT JP LU NL SE
AI WO 1990-US848 A 19900214

PRAI	US 1989-310,773	19890214
	US 1989-344,963	19890428
	US 1990-467,147	19900118

=> d L6 1-21 ti

L6 ANSWER 1 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI SYNTHESIS AND BIOLOGICAL ACTIVITY OF CARBOCYCLIC **CLITOCINE**.

L6 ANSWER 2 OF 21 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI SYNTHESIS INTRAMOLECULAR HYDROGEN BONDING AND BIOCHEMICAL STUDIES OF
CLITOCINE A NATURALLY OCCURRING EXOCYCLIC AMINO NUCLEOSIDE.

L6 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
TI In vivo antitumor activity of **clitocine**, an exocyclic amino
nucleoside isolated from *Lepista inversa*

L6 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of nucleoside compounds for nonsense suppression and the treatment of
genetic diseases

L6 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of nucleoside analogs and their use for treating
cancer and diseases associated with somatic mutations of mRNA

L6 ANSWER 6 OF 21 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on
STN
TI Cytotoxic activity of Tricholomatales determined with murine and human
cancer cell lines

L6 ANSWER 7 OF 21 USPATFULL on STN
TI Uses for inhibitors of inosine monophosphate dehydrogenase

L6 ANSWER 8 OF 21 USPATFULL on STN
TI Methods for inhibiting protein kinases in **cancer** cells

L6 ANSWER 9 OF 21 USPATFULL on STN
TI Nucleoside compounds and their use for treating **cancer** and
diseases associated with somatic mutations

L6 ANSWER 10 OF 21 USPATFULL on STN
TI Method of inhibiting transformation of cells in which purine metabolic
enzyme activity is elevated

L6 ANSWER 11 OF 21 USPATFULL on STN
TI Substituted pyrimido[5,4-d]pyrimidine nucleosides

L6 ANSWER 12 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE
TIFR COMPOSES PERMETTANT DE SUPPRIMER LES EFFETS DES MUTATIONS NON-SENS, ET
METHODES D'EMPLOI DESDITS COMPOSES

L6 ANSWER 13 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE
TIFR COMPOSES POUR LA SUPPRESSION DE MUTATIONS NON-SENS ET PROCEDES
D'UTILISATION ASSOCIES

L6 ANSWER 14 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE
TIFR COMPOSES POUR LA SUPPRESSION DE MUTATIONS NON-SENS ET PROCEDES
D'UTILISATION ASSOCIES

L6 ANSWER 15 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE

TIFR COMPOSES DE SUPPRESSION DE NON-SENS ET PROCEDES DE LEUR UTILISATION

L6 ANSWER 16 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN THERAPEUTIC INHIBITION OF PROTEIN KINASES IN **CANCER** CELLS
 TIFR INHIBITION THERAPEUTIQUE DES PROTEINES KINASES DANS DES CELLULES
 CANCEREUSES

L6 ANSWER 17 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN NEW USES FOR INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE
 TIFR NOUVELLES UTILISATIONS D'INHIBITEURS DE L'INOSINE MONOPHOSPHATE
 DESHYDROGENASE

L6 ANSWER 18 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN UNUSUAL NUCLEOSIDE LIBRARIES, COMPOUNDS, AND PREFERRED USES AS ANTIVIRAL
 AND ANTICANCER AGENTS
 TIFR BANQUES DE NUCLEOSIDES ET COMPOSES RARES, ET UTILISATIONS PREFEREES
 COMME AGENTS ANTICANCEREUX ET ANTIVIRAUX

L6 ANSWER 19 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN ADENOSINE ANALOGUES AND METHOD OF INCREASING ADENOSINE RELEASE
 TIFR ANALOGUES DE L'ADENOSINE ET PROCEDE D'INTENSIFICATION DE LA LIBERATION
 DE L'ADENOSINE

L6 ANSWER 20 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN
 WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED
 TIFR PROCEDE D'INHIBITION DE LA TRANSFORMATION, DE LA CROISSANCE ET DE LA
 METASTASE DE CELLULES DANS LESQUELLES L'ACTIVITE ENZYMATIQUE METABOLIQUE
 PURIQUE EST ELEVEE

L6 ANSWER 21 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC
 ENZYME ACTIVITY
 TIFR INHIBITION DE LA TRANSFORMATION DE CELLULES AYANT UNE ACTIVITE D'ENZYME
 METABOLIQUE DE PURINE ELEVEE

=> d L7 1-11 ti

L7 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Use of nucleoside compounds for **nonsense** suppression and the
 treatment of genetic diseases

L7 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of nucleoside analogs and their use for treating cancer and
 diseases associated with somatic mutations of mRNA

L7 ANSWER 3 OF 11 USPATFULL on STN
 TI Nucleoside compounds and their use for treating cancer and diseases
 associated with somatic mutations

L7 ANSWER 4 OF 11 USPATFULL on STN
 TI Method of inhibiting transformation of cells in which purine metabolic
 enzyme activity is elevated

L7 ANSWER 5 OF 11 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN COMPOUNDS FOR **NONSENSE** SUPPRESSION, AND METHODS FOR THEIR USE
 TIFR COMPOSES PERMETTANT DE SUPPRIMER LES EFFETS DES MUTATIONS NON-SENS, ET
 METHODES D'EMPLOI DESDITS COMPOSES

L7 ANSWER 6 OF 11 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN COMPOUNDS FOR **NONSENSE** SUPPRESSION, AND METHODS FOR THEIR USE
 TIFR COMPOSES POUR LA SUPPRESSION DE MUTATIONS NON-SENS ET PROCEDES
 D'UTILISATION ASSOCIES

L7 ANSWER 7 OF 11 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE
 TIFR COMPOSES POUR LA SUPPRESSION DE MUTATIONS NON-SENS ET PROCEDES
 D'UTILISATION ASSOCIES

L7 ANSWER 8 OF 11 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE
 TIFR COMPOSES DE SUPPRESSION DE NON-SENS ET PROCEDES DE LEUR UTILISATION

L7 ANSWER 9 OF 11 PCTFULL COPYRIGHT 2006 Univentio on STN

L7 ANSWER 10 OF 11 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN
 WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED
 TIFR PROCEDE D'INHIBITION DE LA TRANSFORMATION, DE LA CROISSANCE ET DE LA
 METASTASE DE CELLULES DANS LESQUELLES L'ACTIVITE ENZYMATIQUE METABOLIQUE
 PURIQUE EST ELEVEE

L7 ANSWER 11 OF 11 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC
 ENZYME ACTIVITY
 TIFR INHIBITION DE LA TRANSFORMATION DE CELLULES AYANT UNE ACTIVITE D'ENZYME
 METABOLIQUE DE PURINE ELEVEE

=> d L9 1-4 ti abs bib

L9 ANSWER 1 OF 4 USPATFULL on STN
 TI Method of inhibiting transformation of cells in which purine metabolic
 enzyme activity is elevated
 AB A method of inhibiting growth, transformation and/or metastasis of
 mammalian cells, particularly epithelial cells, in which activity of at
 least one enzyme, which participates in purine metabolism or regulation
 of nucleotide levels or the relative ratios of their phosphorylated
 states, is elevated. In particular, a method of inhibiting
 transformation, growth and/or metastasis of mammalian cells in which a
 DNA tumor virus, a DNA tumor virus factor or other factor which has an
 equivalent effect on cells has acted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 94:55549 USPATFULL
 TI Method of inhibiting transformation of cells in which purine metabolic
 enzyme activity is elevated
 IN Kaddurah-Daouk, Rima, Watertown, MA, United States
 Lillie, James W., Somerville, MA, United States
 Burbaum, Jonathan J., Cambridge, MA, United States
 PA Amira, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 5324731 19940628
 AI US 1990-610418 19901107 (7)
 RLI Continuation-in-part of Ser. No. US 1990-467147, filed on 18 Jan 1990,
 now abandoned which is a continuation-in-part of Ser. No. US
 1989-344963, filed on 28 Apr 1989, now abandoned which is a
 continuation-in-part of Ser. No. US 1989-310773, filed on 14 Feb 1989,
 now abandoned

DT Utility
 FS Granted
 EXNAM Primary Examiner: Nutter, Nathan M.
 LREP Lahive & Cockfield
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN 40 Drawing Figure(s); 39 Drawing Page(s)
 LN.CNT 2730
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN

AN 2001000840 PCTFULL
no bibliographic data available - please use FPI for PI information

L9 ANSWER 3 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN
WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED
TIFR PROCEDE D'INHIBITION DE LA TRANSFORMATION, DE LA CROISSANCE ET DE LA
METASTASE DE CELLULES DANS LESQUELLES L'ACTIVITE ENZYMATIQUE METABOLIQUE
PURIQUE EST ELEVEE
ABEN A method of inhibiting growth, transformation, and/or metastasis of
mammalian cells,
particularly epithelial cells, in which activity of at least one enzyme,
which participates in
purine metabolism or regulation of nucleotide levels or the relative
ratios of their phosphorylated
states, is elevated. In particular, a method of inhibiting
transformation, growth and/or metastasis
of mammalian cells in which a DNA tumor virus, a DNA tumor virus factor
or other factor which has an
equivalent effect on cells has acted.

ABFR Procede d'inhibition de la croissance, de la transformation et/ou de la
metastase de cellules
mammiferes, notamment de cellules epitheliales, dans lesquelles
l'activite d'au moins une enzyme,
laquelle participe au metabolisme ou a la regulation purique de niveaux
de nucleotides ou aux
rapports relatifs de leurs etats phosphoryles, est elevee. L'invention
concerne notamment un procede
d'inhibition de la transformation, de la croissance et/ou de la
metastase de cellules mammiferes
dans lesquelles un virus oncogene d'ADN, un facteur de virus oncogene
d'ADN ou un autre facteur
ayant un effect equivalent sur les cellules a agi.

AN 1992008456 PCTFULL ED 20020513
TIEN METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN
WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED
TIFR PROCEDE D'INHIBITION DE LA TRANSFORMATION, DE LA CROISSANCE ET DE LA
METASTASE DE CELLULES DANS LESQUELLES L'ACTIVITE ENZYMATIQUE METABOLIQUE
PURIQUE EST ELEVEE
IN KADDURAH-DAOUK, Rima;
LILLIE, James, W.
PA AMIRA, INC.
LA English
DT Patent
PI WO 9208456 A2 19920529
DS W: AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE
AI WO 1991-US8275 A 19911107
PRAI US 1990-610,418 19901107

L9 ANSWER 4 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC
ENZYME ACTIVITY
TIFR INHIBITION DE LA TRANSFORMATION DE CELLULES AYANT UNE ACTIVITE D'ENZYME
METABOLIQUE DE PURINE ELEVEE
ABEN A method of inhibiting growth rate, transformation or metastasis of
mammalian cells,
particularly epithelial cells, in which activity of at least one enzyme
which participates in purine
metabolism and regulation of nucleotide levels is elevated. In
particular, a method of inhibiting
transformation of mammalian cells by a DNA tumor virus, a DNA tumor
virus factor or other factor
which has an equivalent effect on cells.

ABFR Procede permettant d'inhiber le taux de croissance, la transformation ou
metastase de cellules

de mammiferes, notamment de cellules epitheliales, ou l'activite d'un enzyme au moins, participant dans les taux de metabolisme de la purine et de regulation des nucleotides, est elevee. On decrit en particulier un procede permettant d'inhiber la transformation de cellules de mammifere par un virus oncogene de l'ADN, un facteur de virus oncogene de l'ADN, ou par d'autres facteurs ayant un effet semblable sur les cellules.

AN 1990009192 PCTFULL ED 20020513
 TIEN INHIBITING TRANSFORMATION OF CELLS HAVING ELEVATED PURINE METABOLIC
 ENZYME ACTIVITY
 TIFR INHIBITION DE LA TRANSFORMATION DE CELLULES AYANT UNE ACTIVITE D'ENZYME
 METABOLIQUE DE PURINE ELEVEE
 IN KADDURAH-DAOUK, Rima;
 DAOUK, Ghaleb;
 SCHIMMEL, Paul, R.;
 KINGSTON, Robert;
 LILLIE, James, W.;
 GREEN, Michael;
 PUTNEY, Scott, D.
 PA MASSACHUSETTS INSTITUTE OF TECHNOLOGY;
 HARVARD UNIVERSITY
 LA English
 DT Patent
 PI WO 9009192 A1 19900823
 DS W: AT AU BE CA CH DE DK ES FR GB IT JP LU NL SE
 AI WO 1990-US848 A 19900214
 PRAI US 1989-310,773 19890214
 US 1989-344,963 19890428
 US 1990-467,147 19900118

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
54.56	68.79

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 10:21:19 ON 25 MAY 2006

=> d hist

(FILE 'HOME' ENTERED AT 14:40:34 ON 25 MAY 2006)

FILE 'STNGUIDE' ENTERED AT 14:41:20 ON 25 MAY 2006

FILE 'BIOSIS, CAPLUS, EMBASE, PASCAL, SCISEARCH, USPATFULL, PCTFULL'
ENTERED AT 14:41:27 ON 25 MAY 2006

L1	107 S CLITOCINE/BI OR 105798-74-1/BI
L2	79 S L1 NOT PY>2002
L3	42 DUP REM L2 (37 DUPLICATES REMOVED)
L4	0 S L3 AND NONSENSE(W) SUPPRES?
L5	0 S L3 AND NONSENSE
L6	4 S L3 AND TRANSLATION
L7	0 S L3 AND GENETIC(W) DISEASE